TAMPA, Fla. – Moffitt Cancer Center will play a key role at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 30 to June 3 in Chicago. Physician-scientists and researchers from Moffitt are contributing to more than 30 oral, rapid-oral and poster presentations, offering new data and perspectives that could help shape the future of cancer care. This year’s ASCO theme, “Driving Knowledge to Action. Building a Better Future,” reflects a shared commitment to turning scientific discoveries into meaningful outcomes for patients.
Moffitt will be prominently featured at this year’s ASCO Annual Meeting, including a plenary presentation on polycythemia vera. Additional highlights include several oral presentations on melanoma, renal cell carcinoma and head and neck squamous cell carcinoma. Moffitt researchers will also present multiple posters covering a wide range of cancer types, including lung, breast, cervical and biliary tract cancers.
For a complete list of presentations, please visit Moffitt.org/ASCO .
Plenary Session:
LBA3: Results from VERIFY, a phase 3, double-blind, placebo-controlled study of rusfertide for treatment of polycythemia vera
Sunday, June 1, 2:09-2:21 p.m. CT, Hall B
Andrew Kuykendall, MD
Melanoma/Skin Cancer Late Breaking Abstracts:
LBA9505: A phase II randomized study of neoadjuvant pembrolizumab alone or in combination with vidutolimod in high-risk resectable melanoma: ECOG-ACRIN EA6194
Tuesday, June 3, 11:09-11:21 a.m. CT, S100a
Ahmad Tarhini, MD, PhD
LBA9507: A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013)
Tuesday, June 3, 11:57 a.m.-12:09 p.m. CT, S100a
Zeynep Eroglu, MD
Rapid Oral Sessions:
4515: Zanzalintinib + nivolumab ± relatlimab in patients with previously untreated clear cell renal cell carcinoma: Results from an expansion cohort of the phase 1b STELLAR-002 study
Friday, May 31, 1:21-1:27 p.m. CT, Arie Crown Theater
Jad Chahoud, MD, MPH, MHA
6017: Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial
Sunday, June 1, 12:12-12:18 p.m. CT, E450a
Christine Chung, MD
9514: A phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma
Monday, June 2, 10:27-10:33 a.m. CT, E451
Andrew Brohl, MD
9516: Infusion product characteristics to predict response to tumor-infiltrating lymphocyte therapy in metastatic melanoma
Monday, June 2, 10:51-10:57 a.m. CT, E451
Lilit Karapetyan, MD, MSc, FACP
9008: Recognizing international medical graduates: Awards and committee membership in ASCO
Monday, June 2, 10:27-10:33 a.m. CT, E350
Karun Neupane, MD
Expert Interviews:
Moffitt experts are available to comment on a wide range of cancer research and care topics before and during the meeting by video call, phone or email. To arrange interviews, contact Kim Polacek ( Kim.Polacek@Moffitt.org ).
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers , a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-970-1205), visit MOFFITT.org , and follow the momentum on Facebook , Twitter , Instagram and YouTube .
###